There is currently no industry standard database for Europe that identifies the location of PET/CT imaging sites and potential commercial cyclotron manufacturing sites. Unlike the US, the European market is fragmented with no true Pan-European manufacturing provider. As PET imaging technology transitions from a research-driven environment to a more commercially-driven one, much of this information is incomplete or not easily available for these markets.


Data availability and analysis across the markets differs substantially. Challenges lie around the necessity to incorporate the data available for each market; the existing forecasts and methodologies currently in place in each market; build on current best practice; and establish a revised forecasting tool that can be adopted on a pan-European scale. The final tool needs to be easy to use, able to be calibrated with local data and capture key marketing initiatives.

Lorem ipsum dolor sit amet, consectetur adipisicing elit. Eum neque alias voluptatem quasi perspiciatis sequi iusto excepturi iure natus saepe minima temporibus, illum laborum! Voluptas odit doloribus ducimus voluptatibus dolores.

XCite me

Many of the innovations being pursued by diagnostic pharmaceutical companies involve the use of F18 to label their radioactive tracers to improve earlier diagnosis in the areas of neurology and oncology. Unlike conventional pharma- ceuticals, radio-labelled products have a finite shelf-life of a few hours. This introduces significant complexity to manufacturing and supply chain components of these new products such as:
• Limited capacity of patient doses able to be produced per cyclotron run
• Restricted travel distance between the imaging facility and manufacturing site due to radioactive decay of product
• Limited imaging facility capacity

Big Idea

To provide senior management with a reporting tool to track product sales and to provide local management with a robust means to support and develop their launch strategies. A detailed dynamic patient switch model was used to capture the complexities around patient management; treatment failures; lines of therapy; and prior exposure to different agents. Also, accompanying training needed to be a major component of the project deliverable to ensure a thorough understanding of the new forecasting methodology and full adoption of the new tool in local planning and reporting.

An intimate understanding of the relationship between supply constraints and potential demand is essential in order to develop a viable market for these new products

Big Idea

To develop a comprehensive and accurate database for T5 EU markets using local market information, secondary research and information from industry associations. Cross-referencing multiple sources will ensure a high level of database accuracy, and data will be reviewed periodically to maintain its validity. The advantage of this tool will be its ability to overlay the equipment infrastructure, including cyclotrons and PET scanners; the location of imaging physicians; and crucial product profile characteristics. Clients would be provided with a clear picture of a product supply and likely demand in any given territory, with visibility of potential barriers to commercial success.

This user friendly web-based tool is able to provide rapid, relevant analyses for companies interested in developing assets in this space. Information can be accessed on either an ad-hoc or subscription basis giving companies the ability to generate an analysis from a single market or Pan-European perspective. Users have the ability to enter key product profile attributes to generate a comprehensive market picture. 

This type of analysis will enable clients to identify maximum revenue potential within the catchment of any given manufacturing site as well as an outline of the potential costs associated with production. This versatile tool will provide companies as well as investors with a clear perspective on the potential profitability of their products.